124 related articles for article (PubMed ID: 33823471)
41. Treatment with renin-angiotensin system inhibitors and prognosis of heart failure with preserved ejection fraction: A propensity-matched study in the community.
Egido JJ; Gomez R; Romero SP; Andrey JL; Ramirez D; Rodriguez A; Pedrosa MJ; Gomez F
Int J Clin Pract; 2019 Jun; 73(6):e13317. PubMed ID: 30694579
[TBL] [Abstract][Full Text] [Related]
42. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
Shih CJ; Chu H; Ou SM; Chen YT
Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
[TBL] [Abstract][Full Text] [Related]
43. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes.
Campbell HM; Khan N; Raisch DW; Borrego ME; Sather MR; Murata GH
Diabetes Res Clin Pract; 2013 Dec; 102(3):233-41. PubMed ID: 24183258
[TBL] [Abstract][Full Text] [Related]
44. [Influence of Renin-angiotensin System Blockage on Recurrence of Non-muscle-invasive Bladder Cancer].
Bai YJ; Wang XM; Han P; Yang YB; Tang Y; Wei Q; Wang J
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 49(4):635-639. PubMed ID: 30378319
[TBL] [Abstract][Full Text] [Related]
45. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
46. Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
Lin TT; Yang YH; Liao MT; Tsai CT; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
Kidney Int; 2015 Aug; 88(2):378-85. PubMed ID: 25807037
[TBL] [Abstract][Full Text] [Related]
47. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
48. Angiotensin-converting enzyme inhibitors and bacterial pneumonia in patients with Parkinson disease.
Wang HC; Lin CC; Lau CI; Chang A; Kao CH
Mov Disord; 2015 Apr; 30(4):593-6. PubMed ID: 25641619
[TBL] [Abstract][Full Text] [Related]
49. Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma.
Chen YH; Huang CH; Lu HI; Chen CH; Huang WT; Hsieh MJ; Rau KM; Chang AY; Lin WC; Li SH
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1185-92. PubMed ID: 24961505
[TBL] [Abstract][Full Text] [Related]
50. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.
Al Khalaf MM; Thalib L; Doi SA
Am J Cardiovasc Drugs; 2009; 9(1):29-43. PubMed ID: 19178130
[TBL] [Abstract][Full Text] [Related]
51. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
[TBL] [Abstract][Full Text] [Related]
52. A Study of Morphological Changes in Renal Afferent Arterioles Induced by Angiotensin II Type 1 Receptor Blockers in Hypertensive Patients.
Nagai Y; Yamabe F; Sasaki Y; Ishii T; Nakanishi K; Nakajima K; Shibuya K; Mikami T; Akasaka Y; Urita Y; Yamanaka N
Kidney Blood Press Res; 2020; 45(2):194-208. PubMed ID: 31945766
[TBL] [Abstract][Full Text] [Related]
53. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
[TBL] [Abstract][Full Text] [Related]
54. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.
Kunz R; Friedrich C; Wolbers M; Mann JF
Ann Intern Med; 2008 Jan; 148(1):30-48. PubMed ID: 17984482
[TBL] [Abstract][Full Text] [Related]
55. The addition of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors--what has time told us?
Fabi MR; Teerlink JR
Curr Heart Fail Rep; 2005 Aug; 2(2):59-64. PubMed ID: 16036052
[TBL] [Abstract][Full Text] [Related]
56. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.
Bangalore S; Fakheri R; Toklu B; Ogedegbe G; Weintraub H; Messerli FH
Mayo Clin Proc; 2016 Jan; 91(1):51-60. PubMed ID: 26763511
[TBL] [Abstract][Full Text] [Related]
57. Hyperkalemia of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in hemodialysis: a meta-analysis.
Zhang Q; Luan H; Wang L; Zhang M; Chen Y; Lv Y; Ma Z
J Huazhong Univ Sci Technolog Med Sci; 2012 Oct; 32(5):785-792. PubMed ID: 23073814
[TBL] [Abstract][Full Text] [Related]
58. Association between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury.
Suberviola B; Rodrigo E; González-Castro A; Serrano M; Heras M; Castellanos-Ortega Á
Med Intensiva; 2017; 41(1):21-27. PubMed ID: 28341094
[TBL] [Abstract][Full Text] [Related]
59. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
60. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials.
Madrid AH; Peng J; Zamora J; Marín I; Bernal E; Escobar C; Muños-Tinoco C; Rebollo JM; Moro C
Pacing Clin Electrophysiol; 2004 Oct; 27(10):1405-10. PubMed ID: 15511250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
